NCT02966730 - Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 20, 2019

Study Completion Date

June 20, 2019

Conditions

Follicular LymphomaFollicular Lymphoma, Grade 1Follicular Lymphoma, Grade 2Follicular Lymphoma Grade IIIa

Interventions

DRUG

Ibrutinib

Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.

Trial Locations (9)

10021

Memorial Sloan - Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

19111

Fox Chase Cancer Center, Philadelphia

29425

Medical University of South Carolina, Charleston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre